Navigation Links
FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
Date:8/14/2014

BRIDGEWATER, N.J., Aug. 14, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the U.S. Food and Drug Administration (FDA) has agreed with the design of our pivotal Phase III protocol for Neutrolin® in Hemodialysis patients, and the company plans to submit the IND for Neutrolin within the next 30 days. The FDA will then have 30 days to respond to the IND.  The pivotal Phase 3 randomized controlled trial ("RCT") for Neutrolin is for use in hemodialysis patients with a central venous catheter.  The Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe.  Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program.

In addition, CorMedix is pleased to announce strategic business collaboration with Wonik Corporation, a South Korean corporation with a strong medical device franchise within the Korean healthcare market.  Wonik has a strong medical franchise and we believe it is well positioned to market, sell and distribute Neutrolin for hemodialysis patients upon receipt of regulatory approval in Korea.

Randy Milby, Chief Executive Officer of CorMedix, stated, "I am very pleased to have signed a definitive agreement with an established commercial partner, Wonik Group in South Korea, a professional and growing healthcare company in one of the key markets in East Asia.  It will of course take some time to gain regulatory approval to market the product."

"In addition, the acceptance of the Neutrolin pivotal Phase 3 clinical trial protocol is a major milestone which provide
'/>"/>

SOURCE CorMedix Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind
2. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
5. Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
6. KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for Release of CereKin Pivotal Study Data
7. BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
8. Pelvalon Announces Results from the LIFE Pivotal Trial at the 2014 AUGS/IUGA Conference
9. Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
10. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
11. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... December 15, 2014 Investor-Edge has initiated ... ZGNX ), Eli Lilly and Company (NYSE: LLY ... SNY ), and Novartis AG (NYSE: ... accessed at: http://investor-edge.com/register . On Friday, December ... the Dow Jones Industrial Average lost 1.79%, to finish the ...
(Date:12/15/2014)... LONDON and BOSTON , ... the leading GPCR structure-guided drug discovery and development company, ... patents in the United States ... of these patents in the US significantly strengthens the ... the major pharmaceutical markets. The suite of ...
(Date:12/13/2014)... Ala. , Dec. 12, 2014 ... purchased the HiSeq X Ten sequencing system manufactured ... enable HudsonAlpha to produce and analyze genomic data ... stems from the Institute,s commitment to research programs ... The HiSeq X Ten provides unprecedented capacity, speed ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... YORK, April 20, 2011 Reportlinker.com announces that a ... Successful Strategies for Drug Repositioning ... Introduction This report Highlights ... to drug development. The success of the approach is ...
... Sagent Pharmaceuticals (Nasdaq: SGNT ) announced the ... of the offering has been increased from the previously announced ... stock at a price to the public of $16.00 per ... NASDAQ Global Market on April 20, 2011 under the ticker ...
Cached Medicine Technology:Reportlinker Adds Successful Strategies for Drug Repositioning 2Reportlinker Adds Successful Strategies for Drug Repositioning 3Reportlinker Adds Successful Strategies for Drug Repositioning 4Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering 2
(Date:12/15/2014)... CT (PRWEB) December 15, 2014 Kathy ... the prestigious Women World Awards in the category of ... a gold award for her weekly career blog ... practical advice to help professionals elevate their talent and ... Her blog, named after her book Networking Ahead for ...
(Date:12/15/2014)... 15, 2014 In support of ... attention to restrictive state laws that may have ... this important area of public health policy. , ... the Integrity of Independent Review, contends that state ... independent peer review determinations can result in subpar ...
(Date:12/15/2014)... Bacteroides is becoming the indicator of choice ... more prevalent than coliforms, it cannot reproduce in the presence ... , Key Benefits of the new Bacteroides Sewage Screen:, ... Eliminates false positives from coliforms naturally occurring in the ... Maintain the same sampling method with results as ...
(Date:12/15/2014)... For the second year in a row, ... Coffees of 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak ... at number 10. This is the first year that any ... is ranked on quality, value, and other aspects, including certifications ... of 100, and at $17.99 for 12-ounces, was also the ...
(Date:12/15/2014)... Following on the heels of its successful and ... up for another round of holiday cheer. , The ... dispensaries, began the 2014 holiday shopping season with a ... , “We've picked up a lot of new ... CEO and founder, Ryan Fox. , And as Colorado ...
Breaking Medicine News(10 mins):Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2Health News:Colorado’s Grass Station Helps Holiday Shoppers Put Something Special under the Christmas Tree 2
... ... ... Coker has named David Booher as Vice President of Jackson & Coker,s Emergency Medicine ... very capable leader in our accounting and finance department, and his well-rounded abilities in other ...
... ... workplaces for top talent , ... Hudson, OH (PRWEB) September 2, 2009 -- Lexi-Comp, Inc., a leader in providing drug and ... Northeast Ohio,s 99 great workplaces for top talent. The Hudson-based, privately-owned company was founded ...
... , WASHINGTON, Sept. 2 The American ... Council for recommending a solid array of meaningful community actions ... Obesity. Overweight children have a 70 percent chance of ... rise nationwide, our youngsters have substantially greater risks for developing ...
... , , , REDMOND, Wash., Sept. ... senior living and assisted living communities ... of 425 magazine . In the first-ever "Best ... people, places and services. Aegis Living is always developing innovative ways to ...
... , BURBANK, Calif., Sept. 1 Warner Bros. Consumer ... partnership today to reach out to Hispanic mothers and promote healthy, ... The partnership will provide new and expecting mothers with fun, ... babies. Launching in celebration of Hispanic Heritage Month, a special ...
... Magazines that rank facilities don,t take all measurements into account ... make it onto the U.S. News & World Report ... perform well in some measurements regarding heart failure, researchers say. ... compares in the areas of heart failure mortality and readmission, ...
Cached Medicine News:Health News:Jackson & Coker Names David Booher Vice President of Emergency Medicine Recruitment 2Health News:Lexi-Comp, Inc. Receives NorthCoast 99 Honor 2Health News:Lexi-Comp, Inc. Receives NorthCoast 99 Honor 3Health News:Lexi-Comp, Inc. Receives NorthCoast 99 Honor 4Health News:Aegis Living Chosen as Best Retirement Facility in 2009 Best of 425 magazine 2Health News:Video: Renowned Health Expert Dra. Aliza Teams Up With Baby Looney Tunes To Promote Healthy, Happy Babies 2Health News:Video: Renowned Health Expert Dra. Aliza Teams Up With Baby Looney Tunes To Promote Healthy, Happy Babies 3Health News:Video: Renowned Health Expert Dra. Aliza Teams Up With Baby Looney Tunes To Promote Healthy, Happy Babies 4Health News:Government Best Source for U.S. Hospital Data, Study Finds 2
... watt xenon Light Source. ... your commitment to provide every ... care available through our ongoing ... surgical instruments and diagnostic solutions., ...
The new X7000 light source is specifically tuned for the demanding requirements of Progressive Scan High Definition. The X7000 Lightsource uses a 300 Watt Xenon Elliptical Bulb for crystal clear illu...
... 175 watt xenon Light ... , ,SOLOS Endoscopy shares ... patient with the highest quality ... research and development of advanced ...
... need to standardize your video equipment has ... of optical couplers to accommodate all of ... "C and "V mount couplers in both ... designs. We also offer a 20-42mm Zoom ...
Medicine Products: